Tech Company Financing Transactions
Envisagenics Funding Round
On 10/13/2026, Envisagenics received $2 million in funding from National Institutes of Health.
Transaction Overview
Company Name
Announced On
10/13/2026
Transaction Type
Debt
Amount
$2,000,000
Round
Undisclosed
Investors
Proceeds Purpose
This grant will support the development of SpliceDisco. By combining AI-driven prioritization with experimental validation, the project is designed to generate cancer-specific, partner-ready therapeutic target opportunities with defined disease relevance, patient prevalence, and modality fit across Envisagenics' internal oncology pipeline and external collaboration programs.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
101 Ave. of the Americas 3rd Floor
New York, NY 10013
USA
New York, NY 10013
USA
Phone
Website
Email Address
Overview
Envisagenics is a New York City-based a bioinformatics company. Biomedical data might hold the key to finding the cure for currently incurable diseases. Our mission is to reduce the complexity of RNA-seq data into plausible candidates for drug and biomarker development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Maria Pineda
Chief Technical Officer
Martin Akerman
Browse more venture capital transactions:
Prev: 10/13/2026: RedOwl venture capital transaction
Next: 10/13/2026: DCC venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs